VYZULTA (Latanoprostene bunod) is an ophthalmic (eye drop) medication used to reduce pressure in the fluid of the eyes (intraocular pressure) in patients with either ocular hypertension or open-angle glaucoma.
When VYZULTA eye drops are applied, the active ingredient is split into two active moieties: latanoprost and butanediol mononitrate.
Latanoprost increases the amount of aqueous humor (fluid in the eye) that exits the eye, contributing to the lowering of ocular pressure. Butanediol mononitrate releases nitric oxide, which relaxes the trabecular meshwork.
Apply one drop to the affected eye (s) once daily.
If you are using VYZULTA with other eye drops, separate them by at least 5 minutes.
The active ingredient in VYZULTA is latanoprostene bunod.
Inactive ingredients include benzalkonium chloride, citric acid, EDTA, glycerin, polysorbate 80, sodium citrate, and water.
Prostaglandin analogs like VYZULTA may cause changes in the color of the iris and eyelid. VYZULTA increases the amount of melanin in the affected tissue, causing a darkening of the eye. The changes are often permanent, and most likely to affect those with lighter colored eyes. Color change may take months or years to become apparent.
VYZULTA may change the length and thickness of eyelashes. Eyelashed return to normal after stopping VYZULTA.
Do not touch the tip of the applicator to the surface of the eye or other non-sterile surfaces. Doing so may contaminate the product and lead to an infection of the eye.
Remove contact lens 15 minutes before applying VYZULTA.
The most common adverse effects of VYZULTA include:
- Conjunctival edema
- Conjunctival hyperemia
- Conjunctival irritation
- Eye irritation
- Eye pain
- Foreign body sensation
- Instillation site pain
- Ocular hyperemia
- Punctate keratitis